Amylyx Pharmaceuticals

Amylyx Pharmaceuticals presented new data on avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH), at ENDO 2025. A Phase 2b trial showed avexitide 90mg daily significantly reduced hypoglycemic events. Population PK/PD data confirmed sustained therapeutic exposure for 24 hours. The Phase 3 LUCIDITY trial evaluating this dose is underway, with recruitment expected to complete in 2025 and topline data anticipated in H1 2026. Avexitide has FDA Breakthrough Therapy designation for PBH.